Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06132828 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Mar 30, 2026 to Jul 30, 2027
    • Study completion date: Jul 30, 2026 to Sep 30, 2027
    v6
  2. Enrollment target: 182 to 216
    • Eligibility criteria expanded, about 145 words
    • Study arms: 1 to 2
    v5
  3. Re-verified, no change to tracked fieldsv4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 1, 2023 to Nov 27, 2023
    v3
  5. Eligibility criteria revisedv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is to characterize the safety,tolerability, pharmacokinetics(PK),and preliminary anti-tumor activity of DR30206, in subjects with advanced or metastatic solid tumors
Trial Details
NCT Number NCT06132828
Lead Sponsor Zhejiang Doer Biologics Co., Ltd.
Conditions
(from sponsor)		 Solid Tumor
Enrollment 216 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov